[{"id":5,"run_id":2,"as_of":"2026-08-08","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":60.3,"technical":56.2,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.04 vs the 0.15 threshold (genuine chop)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":24.39,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":15.5,"Volatility behaviour":9.5,"Cross-asset confirmation":13.0,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.3},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":40.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-08T19:39:50.085595+00:00"},{"id":72,"run_id":6,"as_of":"2026-08-10","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":60.3,"technical":56.2,"stage":"Late Extension","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.10 vs the 0.15 threshold (genuine chop)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":29.45,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":15.5,"Volatility behaviour":9.5,"Cross-asset confirmation":13.0,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.3},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":42.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-10T16:32:51.801846+00:00"},{"id":658,"run_id":17,"as_of":"2026-08-11","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":59.4,"technical":55.1,"stage":"Late Extension","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.13 vs the 0.15 threshold (borderline, watch for resolution)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":31.06,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.0,"Volatility behaviour":9.5,"Cross-asset confirmation":13.6,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.3},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":43.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-11T15:02:55.030268+00:00"},{"id":1242,"run_id":27,"as_of":"2026-08-12","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":59.9,"technical":55.8,"stage":"Late Extension","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.12 vs the 0.15 threshold (borderline, watch for resolution)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":30.02,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.0,"Volatility behaviour":9.5,"Cross-asset confirmation":14.1,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.3},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":44.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-12T16:17:35.947482+00:00"},{"id":1305,"run_id":31,"as_of":"2026-08-13","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":59.3,"technical":55.0,"stage":"Late Extension","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.11 vs the 0.15 threshold (genuine chop)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":29.5,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.0,"Volatility behaviour":9.5,"Cross-asset confirmation":13.5,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.3},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":45.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-13T00:11:32.116666+00:00"},{"id":1951,"run_id":41,"as_of":"2026-08-14","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":58.8,"technical":54.4,"stage":"Late Extension","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.15 vs the 0.15 threshold (borderline, watch for resolution)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":32.34,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.0,"Volatility behaviour":9.5,"Cross-asset confirmation":13.0,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.3},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":46.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-14T01:48:05.981934+00:00"},{"id":3187,"run_id":53,"as_of":"2026-08-17","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":60.0,"technical":56.0,"stage":"Late Extension","gated":false,"n_gates":0,"gates":[],"sizing_low":10000.0,"sizing_high":14000.0,"sizing_label":"Probe","close":35.12,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":15.3,"Volatility behaviour":9.5,"Cross-asset confirmation":13.0,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":15.2},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":49.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-17T16:20:45.815019+00:00"},{"id":3772,"run_id":64,"as_of":"2026-08-18","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":53.5,"technical":56.0,"stage":"Late Extension","gated":false,"n_gates":0,"gates":[],"sizing_low":4000.0,"sizing_high":7000.0,"sizing_label":"Probe","close":33.8,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.9,"Volatility behaviour":9.5,"Cross-asset confirmation":13.4,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":8.7},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":50.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-18T18:49:14.813074+00:00"},{"id":4441,"run_id":80,"as_of":"2026-08-19","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":55.2,"technical":58.1,"stage":"Late Extension","gated":false,"n_gates":0,"gates":[],"sizing_low":4000.0,"sizing_high":7000.0,"sizing_label":"Probe","close":33.11,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.8,"Volatility behaviour":9.5,"Cross-asset confirmation":15.2,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":8.7},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":51.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-19T23:06:33.541677+00:00"},{"id":4567,"run_id":113,"as_of":"2026-08-20","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":54.4,"technical":57.1,"stage":"Late Extension","gated":false,"n_gates":0,"gates":[],"sizing_low":4000.0,"sizing_high":7000.0,"sizing_label":"Probe","close":32.1,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.5,"Volatility behaviour":9.5,"Cross-asset confirmation":14.7,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":8.7},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":52.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-20T21:53:10.611004+00:00"},{"id":5241,"run_id":173,"as_of":"2026-08-21","ticker":"FTH","company":"Faeth Therapeutics, Inc.","source":"weekly","conviction":55.5,"technical":58.5,"stage":"Late Extension","gated":false,"n_gates":0,"gates":[],"sizing_low":4000.0,"sizing_high":7000.0,"sizing_label":"Probe","close":32.0,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":14.7,"Volatility behaviour":9.5,"Cross-asset confirmation":15.6,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":8.7},"total_cfo_value":1133317.0,"total_other_value":1397168.0,"n_cfo_buys":3.0,"n_other_buys":4.0,"has_cfo_buy":true,"roles_buying":"3 CFO, 1 CEO, 3 Unclassified","npr":0.1947453555503935,"cluster_insiders":3.0,"days_since_buy":53.0,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-08-21T20:52:35.383879+00:00"}]